Unlabelled: Methyl-L-(11)C-methionine ((11)C-MET) PET has been shown to detect brain tumors with a high sensitivity and specificity. In this study, we investigated the potential of (11)C-MET PET to noninvasively detect tumor progression in patients with gliomas. Moreover, we analyzed the relationship between changes in (11)C-MET uptake on PET and changes in various molecular immunohistochemical markers during progression of gliomas.
Methods: Twenty-four patients with histologically proven glioma were investigated repeatedly with (11)C-MET PET. (11)C-MET uptake was determined for a circular region of interest. Histologic and molecular analyses for tumor progression were performed after open surgery and stereotactic biopsy, respectively.
Results: In patients with malignant progression, the mean increase in (11)C-MET uptake was 54.4% (SD, 45.5%; range, 3.1%-162.2%), whereas in patients without a change in tumor grade, mean (11)C-MET uptake did not significantly change (3.9%; SD, 13.7%; range, -24.4% to 26.3%). The difference in the change in (11)C-MET uptake between the group with malignant progression and the group without malignant progression was highly significant (P < 0.001). Receiver-operating-curve analysis revealed a sensitivity of 90% and a specificity of 92.3% for the detection of malignant transformation by an increase in (11)C-MET uptake of more than 14.6%. Increased (11)C-MET uptake of more than 14.6% was indicative of malignant progression in all but 3 leave-one-out iterations. A detailed immunohistochemical analysis demonstrated a significant correlation between changes in (11)C-MET uptake and the expression of vascular endothelial growth factor.
Conclusion: These data suggest that (11)C-MET-PET represents a noninvasive method to detect malignant progression in patients with gliomas. Moreover, the increase in (11)C-MET uptake during malignant progression is reflected by an increase in angiogenesis-promoting markers as vascular endothelial growth factor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.109.065904 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[11C]-methionine positron emission tomography in the evaluation of pediatric low-grade gliomas.
Neurooncol Adv
April 2024
Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Article Synopsis
- - The study explored the effectiveness of [C]-Methionine PET imaging in diagnosing pediatric low-grade gliomas (pLGGs), revealing its high sensitivity (93%) for both newly diagnosed and previously treated cases.
- - Researchers assessed tumor-to-brain uptake ratios (TBR) and metabolic tumor volumes in 44 patients, finding that TBR significantly decreased after treatment, indicating a response to therapy.
- - The results suggest that [C]-MET-PET is a useful tool for evaluating pLGGs, with potential variances in imaging characteristics among different tumor types and genetic markers, although statistical analyses were limited by small sample sizes.
A comparison study of dynamic [F]Alfatide II imaging and [C]MET in orthotopic rat models of glioblastoma.
J Cancer Res Clin Oncol
April 2024
Department of Nuclear Medicine, First Medical Center of Chinese PLA General Hospital, Fuxing Road 28, Beijing, 100853, China.
Purpose: To investigate and compare the dynamic positron emission tomography (PET) imaging with [F]Alfatide II Imaging and [C]Methionine ([C]MET) in orthotopic rat models of glioblastoma multiforme (GBM), and to assess the utility of [F]Alfatide II in detecting and evaluating neoangiogenesis in GBM.
Methods: [F]Alfatide II and [C]MET were injected into the orthotopic GBM rat models (n = 20, C6 glioma cells), followed by dynamic PET/MR scans 21 days after surgery of tumor implantation. On the PET image with both radiotracers, the MRI-based volume-of-interest (VOI) was manually delineated encompassing glioblastoma.
Meningioma grading based on positron emission tomography: A systematic review and meta-analysis.
World Neurosurg X
April 2023
Department of Neurosurgery, University of Ioannina, School of Medicine, Greece.
Introduction: Meningiomas are the most common central nervous system tumor in adults. Knowledge of the tumor grade can guide optimal treatment timing and shape personalized follow-up strategies. Positron emission tomography (PET) has been utilized for the metabolic assessment of various intracranial space-occupying lesions.
View Article and Find Full Text PDFImaging joint infections using D-methyl-C-methionine PET/MRI: initial experience in humans.
Eur J Nucl Med Mol Imaging
September 2022
Department of Radiology and Biomedical Imaging, University of California, 185 Berry Street, San Francisco, CA, 94107, USA.
Purpose: Non-invasive imaging is a key clinical tool for detection and treatment monitoring of infections. Existing clinical imaging techniques are frequently unable to distinguish infection from tumors or sterile inflammation. This challenge is well-illustrated by prosthetic joint infections that often complicate joint replacements.
View Article and Find Full Text PDFPET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Clin Nucl Med
July 2022
From the Department of Neurosurgery.
Article Synopsis
- The study aimed to determine if 11C-methyl-l-methionine PET scans can predict outcomes for patients with IDH-mutant lower-grade glioma after stopping temozolomide (TMZ) chemotherapy.
- Researchers analyzed data from 30 patients, focusing on the tumor-to-normal brain tissue ratio from PET scans and various predictive factors like age, treatment courses, and MGMT gene status to assess progression-free survival (PFS).
- The findings indicated that both the PET scan results and MGMT methylation status are strong independent predictors of patient outcomes, suggesting that combining these methods improves prediction accuracy for disease progression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!